The mRNA expression of the members of the IGF-system in bovine corpus luteum during induced luteolysis.
The components of the IGF-system were shown to be differentially regulated in bovine antral follicles and corpora lutea (CL) during different stages of the estrous cycle, and to have important functions for specific stages. The aim of this study was to investigate the detailed pattern of mRNA expression of most constituents of the IGF-system and their possible involvement in prostaglandin (PG)F2alpha-induced luteolysis in the bovine CL. Therefore, cows in the mid-luteal phase (days 8-12) were injected with the PGF2alpha-analogue Cloprostenol, and CL were collected by transvaginal ovariectomy at 2, 4, 12, 48 and 64 h after PGF2alpha-injection. Real-time RT-PCR using SYBR Green I detection was employed to determine mRNA expressions of the following factors: ubiquitin (UBQ), insulin-like growth factor I (IGF I), IGF II, IGF-receptor type 1 (IGFR-1), growth hormone receptor (GH-R) and IGF-binding proteins-1-6 (IGFBP-1-6). Total extractable RNA decreased with ongoing luteolysis. IGFBP-1 mRNA was significantly up-regulated at 2h after PGF2alpha and maximal at 4h with a 34-fold increase. IGFBP-5 mRNA was significantly up-regulated after 12h with a maximum of an 11-fold increase at 64 h. For GH-R, IGFR-1, IGF II, IGFBP-3 and -4 mRNA expression, we found a significant down-regulation in certain stages. There was a significant up-regulation for IGFBP-2 and -6 mRNA at 64 h after induced luteolysis. There were no significant changes in IGF I mRNA expression. In conclusion, the IGF-system with all its components seems to play an important role in the very complex process of PGF2alpha-induced luteolysis in bovine CL.
Neuvians
T P
TP
Institute of Physiology, Technical University Munich, Weihenstephaner Berg 3, Freising-Weihenstephan D-85350, Germany.
Pfaffl
M W
MW
Berisha
B
B
Schams
D
D
D000818:Animals; D002417:Cattle; D003008:Cloprostenol / Q000494:pharmacology; D003338:Corpus Luteum / Q000737:chemistry*; D015237:Dinoprost / Q000494:pharmacology; D005260:Female; D015870:Gene Expression; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000235:genetics; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000235:genetics; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000235:genetics; D018974:Insulin-Like Growth Factor Binding Protein 4 / Q000235:genetics; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000235:genetics; D018976:Insulin-Like Growth Factor Binding Protein 6 / Q000235:genetics; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D007335:Insulin-Like Growth Factor II / Q000235:genetics; D003341:Luteolysis / Q000187:drug effects / Q000378:metabolism*; D010052:Ovariectomy; D011374:Progesterone / Q000097:blood; D012333:RNA, Messenger / Q000032:analysis*; D017526:Receptor, IGF Type 1 / Q000235:genetics; D011986:Receptors, Somatotropin / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013002:Somatomedins / Q000235:genetics*
D018970:Insulin-Like Growth Factor Binding Protein 1; D018971:Insulin-Like Growth Factor Binding Protein 2; D018972:Insulin-Like Growth Factor Binding Protein 3; D018974:Insulin-Like Growth Factor Binding Protein 4; D018975:Insulin-Like Growth Factor Binding Protein 5; D018976:Insulin-Like Growth Factor Binding Protein 6; D012333:RNA, Messenger; D011986:Receptors, Somatotropin; D013002:Somatomedins; D003008:Cloprostenol; D011374:Progesterone; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D015237:Dinoprost; D017526:Receptor, IGF Type 1